Methanesulfonic acid (1S,2R)-1-ethyl-2-isoselenocyanato-propyl ester | 804552-76-9

• 分子结构分类: 有机化合物 - 有机盐
• 英文名称: Methanesulfonic acid (1S,2R)-1-ethyl-2-isoselenocyanato-propyl ester
• CAS: 804552-76-9
• 化学式: C₇H₁₃NO₃SSe
• 分子量: 270.211
• InChiKey: MTMFCYMBZYZGMV-RQJHMYQMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  64.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  Methanesulfonic acid (1S,2R)-1-ethyl-2-isoselenocyanato-propyl ester 在 ammonium hydroxide 作用下， 以 1,4-二氧六环 为溶剂， 反应 1.0h， 以0.11 g的产率得到(4R,5R)-5-Ethyl-4-methyl-selenazolidine-2-ylideneamine
  参考文献：
  名称：

  Novel and orally bioavailable inducible nitric oxide synthase inhibitors: synthesis and evaluation of optically active 4,5-dialkyl-2-iminoselenazolidine derivatives

  摘要：

  We have previously reported that (4R,5R)-5-ethyl-2-imino-4-methylthiazolidine (3) strongly inhibits inducible nitric oxide synthase (iNOS). In a successive search for strong and selective iNOS inhibitors, we, herein, describe the synthesis of the selenium analogue of 3 (4: ES-2133) and its related optically active compounds and examine their in vitro and in vivo inhibitory activity against iNOS. In addition, an alternative synthetic method to the selected compound 4 and its pharmacokinetic profile is also reported. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.01.013
• 作为产物：
  描述：

  Methanesulfonic acid (1S,2R)-1-ethyl-2-isocyano-propyl ester 在 selenium 、 三乙胺 作用下， 以 氯仿 为溶剂， 生成 Methanesulfonic acid (1S,2R)-1-ethyl-2-isoselenocyanato-propyl ester
  参考文献：
  名称：

  Novel and orally bioavailable inducible nitric oxide synthase inhibitors: synthesis and evaluation of optically active 4,5-dialkyl-2-iminoselenazolidine derivatives

  摘要：

  We have previously reported that (4R,5R)-5-ethyl-2-imino-4-methylthiazolidine (3) strongly inhibits inducible nitric oxide synthase (iNOS). In a successive search for strong and selective iNOS inhibitors, we, herein, describe the synthesis of the selenium analogue of 3 (4: ES-2133) and its related optically active compounds and examine their in vitro and in vivo inhibitory activity against iNOS. In addition, an alternative synthetic method to the selected compound 4 and its pharmacokinetic profile is also reported. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.01.013